PathAI

PathAI builds AI-powered pathology software that helps laboratories and pharmaceutical companies analyze tissue samples with greater accuracy and efficiency. The company's flagship product, AISight, is a cloud-native digital pathology platform that serves as a central hub for case management, slide image management, and AI-powered diagnostic applications across histopathology workflows.

PathAI received FDA 510(k) clearance for AISight Dx in 2022, and in 2025 obtained additional FDA clearance with a Predetermined Change Control Plan (PCCP) that allows specific future AI enhancements without new regulatory submissions. This regulatory approach positions PathAI ahead of most competitors in the digital pathology space.

The platform's AI algorithms are trained on over 15 million pathologist-verified annotations and can detect and grade cancers across multiple tumor types including breast, lung, head and neck, and gastrointestinal cancers. For biopharma clients, PathAI provides standardized biomarker quantification for clinical trials, helping pharmaceutical companies evaluate drug efficacy with consistent, reproducible pathology data.

PathAI operates the Precision Pathology Network (PPN), launched in 2025, which connects laboratories globally to share AI-powered pathology tools, monetize real-world pathology data, and support biopharma-sponsored evidence generation studies. The company also maintains an in-house CAP/CLIA-certified GCLP histopathology lab for end-to-end clinical trial support.

With approximately $240M in funding raised and partnerships with 90% of the top 15 biopharma companies, PathAI targets enterprise deployments at academic medical centers, reference laboratories, integrated delivery networks, and pharmaceutical companies. Notable partnerships include Moffitt Cancer Center and Quest Diagnostics.